INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 195 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2015. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $878,000 | -18.2% | 8,083 | +23.9% | 0.00% | 0.0% |
| Q3 2016 | $1,074,000 | +17.4% | 6,526 | +1.8% | 0.00% | 0.0% |
| Q2 2016 | $915,000 | +19.1% | 6,410 | +7.3% | 0.00% | 0.0% |
| Q1 2016 | $768,000 | -66.1% | 5,975 | -60.6% | 0.00% | -66.7% |
| Q4 2015 | $2,264,000 | -9.4% | 15,158 | +0.6% | 0.00% | 0.0% |
| Q3 2015 | $2,500,000 | -35.5% | 15,070 | -6.1% | 0.00% | -40.0% |
| Q2 2015 | $3,876,000 | +24.8% | 16,056 | +45.8% | 0.01% | +25.0% |
| Q1 2015 | $3,105,000 | +374.0% | 11,011 | +162.2% | 0.00% | +300.0% |
| Q4 2014 | $655,000 | -35.8% | 4,199 | -2.6% | 0.00% | 0.0% |
| Q3 2014 | $1,020,000 | -2.8% | 4,309 | -2.8% | 0.00% | 0.0% |
| Q2 2014 | $1,049,000 | -83.9% | 4,433 | -77.6% | 0.00% | -88.9% |
| Q1 2014 | $6,527,000 | +385.6% | 19,791 | +0.6% | 0.01% | +350.0% |
| Q4 2013 | $1,344,000 | -1.5% | 19,678 | -0.4% | 0.00% | 0.0% |
| Q3 2013 | $1,364,000 | +85.3% | 19,764 | +20.5% | 0.00% | +100.0% |
| Q2 2013 | $736,000 | – | 16,408 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |